Skip to main content
. 2020 Sep 29;15(10):1433–1444. doi: 10.2215/CJN.14901219

Figure 4.

Figure 4.

Figure 4.

Empagliflozin consistently slowed the long-term annual decline in eGFR across all patient subgroups regardless of KDIGO risk category, as assessed by mean eGFR (Modification of Diet in Renal Disease [MDRD]) slopes on the basis of random intercept/random coefficient models. Adjusted mean eGFR across subgroups of KDIGO risk category. Empa, empagliflozin.